Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth
Source: SeekingAlpha
2025-11-21 16:03:13 ET
In my article from October, "My Top 5 Biotech Stocks Big Pharma Could Buy Next," I mentioned how Phathom Pharmaceutical's ( PHAT ) Voquezna and Voquezna Triple Pak is actively capturing share in the U.S. GERD and H. pylori infection treatment markets. ...
Read the full article on Seeking Alpha
For further details see:
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth
Novartis AG
NASDAQ: NVS
NVS Trading
0.21% G/L:
$143.67 Last:
906,959 Volume:
$142.47 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
